Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 14/20 | 0.76 |
| ▸ | EHMT1 | Q9H9B1 | 13/20 | 0.76 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636829 | 1.00 | EHMT2 (0.76) | EHMT2EHMT1DNMT1EGFRFGFR2 | |
| SCHEMBL2748129 | 0.99 | EHMT2 (0.74) | EHMT2EHMT1DNMT1EGFRFGFR2 | |
| Hydrochloric Acid SCHEMBL6433786 | 0.99 | EHMT2 (0.74) | EHMT2EHMT1DNMT1EGFRFGFR2 | |
| SCHEMBL2746706 | 0.94 | EHMT2 (0.67) | EHMT2EHMT1DNMT1EGFRFGFR1 | |
| SCHEMBL2152700 | 0.92 | EHMT2 (0.64) | EHMT2EHMT1EGFRFGFR1FLT1 | |
| SCHEMBL903068 | 0.90 | EGFR (0.64) | EHMT2EHMT1EGFRFGFR1FLT1 | |
| SCHEMBL2152791 | 0.90 | EHMT2 (0.62) | EHMT2EHMT1EGFR | |
| SCHEMBL5097860 | 0.90 | EGFR (0.64) | EHMT2EHMT1EGFRFGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL6432089 | 0.89 | EGFR (0.62) | EHMT2EHMT1EGFRFGFR1FLT1 | |
| SCHEMBL16707263 | 0.86 | EHMT2 (0.56) | EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021035101-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-25 | — | — | WO | disclosed |
| EP-2799437-B1 | QUINOLINE AND CINNOLINE DERIVATIVES AND USE THEREOF | UNIV SHENYANG PHARMACEUTICAL (CN) | 2016-09-14 | — | — | EP | disclosed |
| US-9382232-B2 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2014-12-11 | — | — | US | disclosed |
| EP-2799437-A1 | QUINOLINE AND CINNOLINE COMPOUNDS AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2014-11-05 | — | — | EP | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | EHMT2 2562/4885EHMT1 2194/4885DNMT1 2932/4885 |
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | MET, CHEK1, KIT | EHMT2 3018/4885EHMT1 2236/4885DNMT1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.